Literature DB >> 2568888

Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts.

Y Kokai1, J N Myers, T Wada, V I Brown, C M LeVea, J G Davis, K Dobashi, M I Greene.   

Abstract

The protein product of the rodent neu oncogene, p185neu, is a tyrosine kinase with structural similarity to the epidermal growth factor receptor (EGFR). Transfection and subsequent overexpression of the human p185c-erbB-2 protein transforms NIH 3T3 cells in vitro. However, NIH 3T3 cells are not transformed by overexpressed rodent p185c-neu. NIH 3T3 transfectants overexpressing EGF receptors are not transformed unless incompletely transformed. Several groups have recently demonstrated EGF-induced, EGFR-mediated phosphorylation of p185c-neu. During efforts to characterize the interaction of p185c-neu with EGFR further, we created cell lines that simultaneously overexpress both p185c-neu and EGFR and observed that these cells become transformed. These observations demonstrate that two distinct, overexpressed tyrosine kinases can act synergistically to transform NIH 3T3 cells, thus identifying a novel mechanism that can lead to transformation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568888     DOI: 10.1016/0092-8674(89)90843-x

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  76 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 2.  ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.

Authors:  R Pinkas-Kramarski; I Alroy; Y Yarden
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

3.  Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

Authors:  A E Lenferink; J F Simpson; L K Shawver; R J Coffey; J T Forbes; C L Arteaga
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

4.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.

Authors:  L N Klapper; S Glathe; N Vaisman; N E Hynes; G C Andrews; M Sela; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 5.  The ERBB network: at last, cancer therapy meets systems biology.

Authors:  Yosef Yarden; Gur Pines
Journal:  Nat Rev Cancer       Date:  2012-07-12       Impact factor: 60.716

6.  Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains.

Authors:  R Murali; P J Brennan; T Kieber-Emmons; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

7.  Targeting Cathepsin B for Cancer Therapies.

Authors:  Hang Ruan; Susan Hao; Peter Young; Hongtao Zhang
Journal:  Horiz Cancer Res       Date:  2015 2nd Quarter

8.  C-erbB-2 immunostaining: problems with interpretation.

Authors:  E W Kay; C J Walsh; M Cassidy; B Curran; M Leader
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

9.  Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface.

Authors:  C L Burke; D F Stern
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

10.  Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha.

Authors:  K Yoshida; H Kuniyasu; W Yasui; Y Kitadai; T Toge; E Tahara
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.